Law
Offices of Howard G. Smith reminds investors that a class action has
been filed on behalf of investors of Insulet Corp. (“Insulet” or the
“Company”) (NASDAQ: PODD), who purchased Insulet securities between
February 27, 2013 and April 30, 2015, inclusive (the “Class Period”).
Insulet investors have until July 6, 2015 to file a lead
plaintiff motion, and are encouraged to contact Howard G. Smith, Esq. to
discuss their legal rights in the pending class action.
Insulet is primarily engaged in the development, manufacturing and sale
of its proprietary OmniPod Insulin Management System (the “OmniPod
System”), an insulin infusion system for people with insulin-dependent
diabetes.
The complaint alleges that Defendants made false and/or misleading
statements, as well as failed to disclose material adverse facts about
the Company’s business, operations, and prospects. Specifically,
Defendants failed to disclose: (1) that the Company was experiencing
slower demand for its products; (2) that the Company was facing issues
with its sales and marketing efforts; (3) that, as a result, the Company
experienced unevenness in its financial performance; and (4) that, as a
result of the foregoing, Defendants’ positive statements about the
Company’s business, operations, and prospects lacked a reasonable basis.
As a result of Defendants’ wrongful acts and omissions, and the
precipitous decline in the market value of the Company’s securities
after disclosing the decline in its revenues, Plaintiff and other Class
members have suffered significant losses and damages.
If you have purchased shares of Insulet and have suffered a loss based
on the recent stock price declines, have information, or would like to
learn more about this matter please contact Howard G. Smith, Esquire, of
Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem,
Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888)
638-4847, or by email to howardsmith@howardsmithlaw.com,
or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150629005927/en/
Copyright Business Wire 2015